OS Increase Observed in Neoadjuvant Pembrolizumab Combo Plus Adjuvant Therapy in Early TNBC
A pembrolizumab regimen significantly improved overall survival (OS) in early-stage triple-negative breast cancer patients, reducing the risk of death by 34% compared to a placebo regimen (HR, 0.66; 95% CI, 0.50-0.87; P = .00150). The 5-year OS rate was 86.6% in the pembrolizumab arm vs 81.7% in the placebo arm.
Reference News
OS Increase Observed in Neoadjuvant Pembrolizumab Combo Plus Adjuvant Therapy in Early TNBC
A pembrolizumab regimen significantly improved overall survival (OS) in early-stage triple-negative breast cancer patients, reducing the risk of death by 34% compared to a placebo regimen (HR, 0.66; 95% CI, 0.50-0.87; P = .00150). The 5-year OS rate was 86.6% in the pembrolizumab arm vs 81.7% in the placebo arm.